Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.21.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
1 Months Ended
Jan. 31, 2010
contingent_value_right_series
contingent_value_right
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of CVR Series | contingent_value_right_series 4    
Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Number of CVRs issued per acquiree share | contingent_value_right 4    
Number of CVRs issued from each CVR series | contingent_value_right 1    
Frequency of cash payments to CVR holders 6 months    
Recurring      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   $ 307,354,000 $ 363,567,000
Liabilities, fair value   51,130,000 49,193,000
Recurring | Contingent liabilities - Crystal      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   800,000 800,000
Recurring | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   496,000 508,000
Recurring | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   4,182,000 3,821,000
Recurring | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   7,439,000 6,404,000
Recurring | Contingent liabilities - Pfenex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   37,900,000 37,600,000
Recurring | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   240,000 0
Recurring | Liability for restricted investments owed to former licensees      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   73,000 60,000
Recurring | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   262,988,000 324,478,000
Recurring | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   44,366,000 32,763,000
Recurring | Investment in warrants      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 6,326,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   52,559,000 42,527,000
Liabilities, fair value   73,000 60,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Crystal      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Pfenex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   73,000 60,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   8,193,000 3,438,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   44,366,000 32,763,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 6,326,000
Recurring | Significant Other Observable Inputs (Level 2)      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   253,373,000 320,647,000
Liabilities, fair value   4,182,000 3,821,000
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Crystal      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   4,182,000 3,821,000
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Pfenex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   253,373,000 320,647,000
Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 0
Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 0
Recurring | Significant Unobservable Inputs (Level 3)      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   1,422,000 393,000
Liabilities, fair value   46,875,000 45,312,000
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Crystal      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   800,000 800,000
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   496,000 508,000
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Metabasis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Icagen      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   7,439,000 6,404,000
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Pfenex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   37,900,000 37,600,000
Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - xCella      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   240,000 0
Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities, fair value   0 0
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   1,422,000 393,000
Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking common stock      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 0
Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Assets, fair value   0 $ 0
Transferred over Time | Phase 3 Clinical Trial      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Gross contract asset   10,000,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investments   $ 375,000,000